Etamzilat instructions for use for children. Etamzilat - instructions for use, indications, side effects, analogues and price. Adverse reactions

INSTRUCTIONS
on the medical use of the drug

Registration number:

P N013946/02

Trade name of the drug:

Dicynon

International non-proprietary name:

etamsylate

Dosage form:

Solution for intravenous and intramuscular administration.

Compound:

Each 2 ml (1 ampoule) solution for intravenous and intramuscular administration contains:
Active substances: etamsylate 250 mg.
Excipients: sodium disulfite 0.84 mg, water for injection up to 2 ml, sodium bicarbonate for pH correction.

Description:
Colorless transparent solution.

Pharmacotherapeutic group:

hemostatic agent.

CodeATX: B02BX01

Pharmacological properties:

Pharmacodynamics
Etamzilat is a hemostatic, antihemorrhagic and angioprotective agent, normalizes the permeability of the vascular wall, improves microcirculation. Stimulates the formation of platelets and their exit from the bone marrow. It increases platelet adhesion, stabilizes capillary walls, thus reducing their permeability, inhibits the synthesis of prostaglandins, which cause platelet disaggregation, vasodilation and increase capillary permeability, which reduces bleeding time and reduces blood loss. Increases the rate of formation of the primary thrombus and enhances its retraction, has virtually no effect on the concentration of fibrinogen in the blood plasma and prothrombin time.
With repeated use, thrombus formation increases.
Etamzilat practically does not affect the composition of peripheral blood, its proteins and lipoproteins. The erythrocyte sedimentation rate may decrease slightly. Reduces the release of fluid and diapedesis of blood cells from the vascular bed, improves microcirculation. Does not have a vasoconstrictive effect.
Possessing anti-hyaluronidase activity and stabilizing ascorbic acid, it prevents destruction and promotes the formation of mucopolysaccharides with a large molecular weight in the capillary wall, increases the resistance of capillaries, reduces their "fragility", and normalizes permeability during pathological processes. This angioprotective effect is manifested in the treatment of various diseases associated with primary and secondary disorders of the microcirculation process.

Pharmacokinetics
The hemostatic effect with intravenous application of etamsylate solution occurs after 5-15 minutes, the maximum effect - after 1-2 hours. The action lasts for 4-6 hours, then gradually weakens within 24 hours. When administered intramuscularly, the hemostatic effect occurs in 30-60 minutes.
After intravenous / intramuscular administration of 500 mg of etamsylate, the maximum plasma concentration is reached after 10 minutes and is 30-50 μg / ml.
Almost completely penetrates the placental barrier. It is not known whether etamsylate passes into breast milk.
About 90% of etamsylate binds to plasma proteins.
Etamsylate is slightly metabolized.
About 80% of the administered dose is excreted through the kidneys unchanged. The plasma half-life after intravenous administration is about 2 hours. About 85% of the administered dose of etamsylate is excreted within 24 hours.
Clinical studies on the use of etamsylate in patients with impaired liver and / or kidney function have not been conducted.

Indications for use

Prevention and treatment of capillary bleeding of various etiologies:

• before, during and after surgical interventions on all well-vascularized tissues in dental, otorhinolaryngological, gynecological, urological, ophthalmic practice, obstetrics and plastic surgery;
• hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, epistaxis, bleeding gums;
• diabetic microangiopathy (hemorrhagic diabetic retinopathy, recurrent retinal hemorrhage, hemophthalmos);
• intracranial hemorrhages in newborns and premature babies.

Contraindications

• Hypersensitivity to the components of the drug.
• Bronchial asthma, confirmed hypersensitivity to sodium sulfite.
• Acute porphyria.
• Hemoblastosis in children (lymphoblastic and myeloid leukemia, osteosarcoma).
• Thromboembolism, thrombosis.

Carefully
Thrombosis, thromboembolism in history; bleeding due to an overdose of anticoagulants.

Use during pregnancy and lactation
There are no clinical data on the possibility of using Dicinon in pregnant women. The use of Dicinon during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
When prescribing the drug during lactation, the issue of stopping breastfeeding should be resolved.

Dosage and administration

Intramuscularly, intravenously.
The optimal daily dose of etamsylate for adults is 10-20 mg / kg of body weight per day, divided into 3-4 doses, as an intramuscular or slow intravenous injection.
Adults
During surgical interventions, 250-500 mg (1-2 ampoules) are administered intravenously or intramuscularly prophylactically or intramuscularly 1 hour before surgery. During the operation, 250-500 mg (1-2 ampoules) of etamsylate are administered intravenously, if necessary, the administration of this dose can be repeated again. After surgery, 250-500 mg (1-2 ampoules) are administered every 4-6 hours until the risk of bleeding disappears.
To stop bleeding, 250-500 mg (1-2 ampoules) are administered intravenously or intramuscularly, after which 250 mg every 4-6 hours for 5-10 days.
In the treatment of metro- and menorrhagia, the drug is used in a single dose of 250 mg intravenously or intramuscularly every 6-8 hours for 5-10 days.
In diabetic microangiopathy, the drug is administered subconjunctival or retrobulbarno at a dose of 125 mg (1/2 ampoule). The drug Dicinon can be applied topically (for example, in the case of a skin graft, after tooth extraction, etc.): a sterile swab or napkin is impregnated with a solution and applied to the wound.
children: adult dose should be reduced by 50%.
In neonatology the drug Dicinon is used intramuscularly at a dose of 10 mg per kg of body weight (0.1 ml = 12.5 mg). Treatment should begin within the first 2 hours after birth, then every 6 hours for 4 days.
If Dicinon is mixed with a 0.9% sodium chloride solution, it should be applied immediately. Side effect

Side effect

According to the World Health Organization (WHO), undesirable effects are classified according to their frequency of development as follows: often (> 1/100,<1/10), нечасто (>1/1000, <1/100), редко (>1/10000, <1/1000) и очень редко (<1/10000), включая отдельные сообщения.
From the digestive system
often: nausea, heaviness in the epigastric region.
From the skin and subcutaneous tissues
often: skin rash;
frequency unknown: flushing of the skin of the face.
From the side of the nervous system
often: headache;
frequency unknown: dizziness, paresthesia of the lower extremities.
From the side of the cardiovascular system
very rarely: thromboembolism, pronounced decrease in blood pressure.
From the blood and lymphatic system
very rarely: agranulocytosis, neutropenia, thrombocytopenia.
From the side of the musculoskeletal system
rarely: arthralgia.
From the side of the immune system
very rarely: allergic reactions.
Other
often: asthenia;
very rarely: fever.

Overdose

To date, no cases of overdose have been described.
If an overdose has occurred, symptomatic therapy should be started.

Interaction with other drugs
Pharmaceutically incompatible (in one syringe) with other drugs.
Dicinon injection solution is incompatible with sodium bicarbonate injection and sodium lactate solution. Administration at a dose of 10 mg/kg 1 hour before dextrans (average molecular weight 30-40 thousand Da) prevents their antiplatelet action.
Action: the introduction after does not have a hemostatic effect.
Perhaps a combination with aminocaproic acid and menadione sodium bisulfite.
Thiamine (vitamin B1) is inactivated by sodium sulfite, which is part of the drug Dicinon.

special instructions

For use in hospitals and clinics only.
Other causes of bleeding should be ruled out before starting treatment. If the color of the solution appears, it should not be used.
The drug is not effective in patients with thrombocytopenia. In hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes.
The use of the drug Dicinon in patients with impaired parameters of the blood coagulation system is possible, but it should be supplemented by the administration of drugs that eliminate the identified deficiency or defect of blood coagulation factors. Due to the increased risk of hypotension (pronounced decrease in blood pressure) with parenteral administration of Dicinon, caution should be exercised in patients with unstable blood pressure or a tendency to hypotension.
Solution for injection Dicinon in its composition contains sodium sulfite as an antioxidant, which can cause allergic reactions, nausea, diarrhea in patients with hypersensitivity to it. Allergic reactions can be severe and manifest as anaphylactic shock and/or life-threatening asthma attacks. The frequency of occurrence is unknown, however, such a pathological reaction is observed more often in patients with bronchial asthma. If such an allergic reaction occurs, the use of the drug Dicinon should be immediately discontinued. Clinical studies on the use of the drug Dicinon in patients with impaired liver and kidney function have not been conducted, therefore, caution should be exercised when using etamsylate in this category of patients.
No special precautions are required for the destruction of unused medicinal product.

Influence on the ability to concentrate
No special precautions required.

Release form

Solution for intravenous and intramuscular injection 125 mg / ml, 2 ml of the drug in an ampoule of colorless neutral glass with a red break point. On the top of the ampoule is a blue ring.
5 or 10 ampoules in a blister, 2 or 5 blisters in a cardboard box along with instructions for use.

Storage conditions

Store at a temperature not exceeding 25°C, protected from light.
Keep out of the reach of children.

Best before date

5 years.
Do not use after the expiration date.

Terms of dispensing from pharmacies

On prescription.

Manufacturer

Lek d.d., Verovshkova 57, 1526 Ljubljana, Slovenia.

Submit consumer complaints
ZAO "Sandoz"
123317, Moscow, Presnenskaya emb., 8, building 1

To combat bleeding, it is difficult to find a drug that is more effective and less hazardous to health, such as Etamzilat. The range of application of this hemostatic agent is very wide, the price is competitive. Therefore, without it, the treatment of most cases of bleeding is not complete.

Indications for use

The inclusion of Etamzilat in therapy is indicated for bleeding in almost any pathological situation. According to the instructions, Etamzilat is the best way to stop capillary bleeding of various etiologies. The drug is effective for heavy periods, it reduces the volume of menstrual flow. When you are worried about long periods, the medicine will help stop your period.

In addition, indications for the use of Etamzilat are:

• damage to the walls of blood vessels in diabetes;
• surgical interventions in dentistry, urology, ophthalmology, gynecology and other medical fields;
• diathesis, accompanied by vascular damage;
• emergency cases, for example, if necessary, to stop bleeding in the intestines, lungs, and other organs.

Composition and form of release

The choice of Etamzilat by most doctors is influenced by a wide variety of its dosage forms. Among them are Etamzilat tablets and injections. In each of these drugs, the active ingredient is Etamzilat. The injections additionally contain water and special sodium salts.

Etamzilat tablets contain 250 mg of the active ingredient, an additive (sodium metabisulphite), calcium salts, starch, common binders. There are 10 or 50 tablets in a blister. In the treatment of children, the drug is prescribed based on the weight of the child. The use of release forms in tablets allows you to adhere to the maximum dosage of 5 mg per 1 kg of body weight in a single dose.

Etamzilat injections are available in packs of 10 pcs. Ampoules of 2 ml solution for injection contain 125 mg of the active ingredient in each milliliter of the drug.

Features of the impact of Etamzilat

Due to the specific pharmacokinetics of the drug, this remedy is successfully used to stop menstruation. For these purposes, many women use Etamzilat tablets. The drug affects the permeability and strength of both capillaries and large blood vessels, strengthening them and making them more elastic. According to the effect on the composition of the blood, the drug is neutral. But due to the activation of platelets after the use of the drug, the blood becomes more viscous.

Read also 🗓 Sanitary tampon Lu Li Meitan - reviews

The drug does not increase the risk of blood clots and does not increase fibrinogen in the blood. At the time of the onset of the blood coagulation process, Etamzilat does not affect.

The effectiveness of this drug and its safety is facilitated by its positive effect on blood flow velocity, improvement of blood microcirculation during its use. These features are the main argument, because of which Etamzilat is prescribed for bleeding. Its action allows you to close the bleeding place in the vessel, but not to disturb the blood flow and its supply to the organs.

Use during pregnancy and lactation

As a rule, Etamzilat during pregnancy is necessary to eliminate the threat of miscarriage. But in the first trimester of pregnancy, injections of the drug are prescribed only when absolutely necessary, as there is a risk of harming the fetus.

For pregnant women in the second trimester or more, this medicine is not dangerous. In case of ectopic pregnancy, the drug is not used. In each case, only the doctor determines how much during pregnancy, taking into account the composition of the blood and other indicators, the use of this remedy is justified.

Since Etamzilat is able to penetrate into breast milk, the drug is not prescribed during lactation.

Method of application and dosage

When using Etamzilat, the instructions for use must be strictly observed. This guide is very accurate and clearly sets out all the conditions under which the use of the drug is possible.

When prescribing tablets, the following dosage is observed:

• 0.25-0.5 mg of the drug 3-4 times a day with moderate bleeding during menstruation;
• 0.75 mg of medication (3 tablets) 3 to 4 times a day with extremely heavy periods;
• 0.5 mg up to 4 times a day, if necessary, to cope with heavy long periods; tablets are drunk for 10 days, starting five days before the onset of menstruation.

With each ingestion, the tablets begin to have an effect after about 20 minutes, the maximum effect will come after 2 or a little more than an hour.

The most effective are injections of the drug. It is administered intravenously and intramuscularly. In the first case, the effect appears almost before our eyes - in less than 10 minutes.

The dosage depends on indications and is appointed by the doctor. According to the instructions, when treating with Etamzilat injections, from 0.125 to 0.250 mg of the drug should be administered at a time, the maximum dose is 0.375 mg. The number of injections - up to 4 times a day.

Read also What to do if there is no menstruation after taking claira

In extreme cases, for example, with bleeding due to the installation of a spiral, you will need to enter up to 6 ampoules per day.

Blood can be stopped with Etamzilat if there is an open wound. To do this, use a tampon moistened with the preparation or a sterile bandage.

Contraindications

Among the factors limiting the use of Etamzilat, first of all, diseases accompanied by the formation of blood clots are mentioned. The main contraindications include:

• vascular diseases;
• thrombosis;
• thromboembolism;
• hemoblastosis;
• porphyria in acute form;
• hemorrhage (as a consequence of the action of anticoagulants);
• oncological diseases;
• individual intolerance.

Many women use Etamzilat during menstruation to reduce them without special need, for example, when the discharge is of medium volume and lasts 5 days. The desire to reduce the period of menstrual days to 3 can lead to serious illness. Only a doctor should prescribe the drug.

Side effects

This drug is characterized by the following side effects:

1. Pressure drop.
2. Headache.
3. Disorders of the stomach, heartburn.
4. Dizziness.
5. Skin rashes, irritation, itching.
6. Temperature rise

Overdose

The main treatment regimen does not involve the occurrence of an overdose. Therefore, cases of exceeding the permissible doses of the drug were not found.

In some cases, in conditions when Etamzilat is used, it is necessary to take into account the possibility of its effect on the body. For example, during treatment with the drug, you should stop breastfeeding your baby.

Taking this medicine in excessive doses does not require special measures. To eliminate possible consequences, it is enough to cancel the drug. Almost the entire amount administered is excreted by the kidneys, so in 3-4 days its content in the blood will no longer pose a threat.

Interaction with other drugs

As an indication of the interaction of Etamzilat with other drugs, the instructions for use require that this drug should not be mixed with any other. It is better to use a separate syringe for this.

Etamzilat's analogs

If for some reason Etamzilat is not suitable for the patient, analogues can successfully replace it. A direct analogue of Etamzilat is the medicine Dicinon. It contains the same active ingredient.

Other drugs, which include substances belonging to other pharmacological groups, can also help to cope with the problem of bleeding. Among them:

• Vikasol;
• Impedil;
• Ezelin;
• Cyclonamine;
• Aglumin and others.

If the patient wishes to replace the currently used Etamzilat with one of the drugs, the specialist should select analogues.

Gross formula

C 10 H 17 NO 5 S

Pharmacological group of the substance Etamzilat

Nosological classification (ICD-10)

CAS code

2624-44-4

Characteristics of the substance Etamzilat

hemostatic agent.

White with a pinkish tint crystalline powder. Easily soluble in water, soluble in alcohol.

Pharmacology

pharmachologic effect- angioprotective, hemostatic.

Stimulates the formation of platelets and their exit from the bone marrow. Activates the formation of tissue thromboplastin (factor III) at the site of damage to small vessels, promotes adhesion and aggregation of platelets, reduces bleeding.

Increases the rate of formation of the primary thrombus and enhances its retraction, with virtually no effect on the level of fibrinogen and PV. With repeated injections, thrombus formation increases.

Restores pathologically altered bleeding time. It does not affect the normal parameters of the hemostasis system. Does not cause hypercoagulability, does not have a vasoconstrictive effect.

Possessing anti-hyaluronidase activity and stabilizing ascorbic acid, it prevents splitting and promotes the formation of mucopolysaccharides with a large molecular weight in the vascular wall, increases the resistance of capillaries, reduces their fragility, and normalizes permeability during pathological processes. Reduces the release of fluid and diapedesis of blood cells from the vascular bed, improves microcirculation.

It is well absorbed both when administered intramuscularly and when taken orally. It is evenly distributed in various organs and tissues (depending on the degree of their blood supply). Weakly binds to proteins and blood cells. It is rapidly excreted from the body almost unchanged, mainly through the kidneys, in small amounts through the intestines. 5 minutes after the IV injection, 20-30% of the administered amount is excreted by the kidneys, completely excreted from the body after 4 hours.

With intravenous administration, activation of hemostasis begins after 5-15 minutes, reaches a maximum after 1-2 hours, remains at a sufficient level for 4-6 hours, and, gradually weakening, stops by the end of the day; with the / m administration, the effect develops somewhat more slowly. When taken orally, the maximum effect is observed after 2-4 hours. After a course of treatment, the effect persists for 5-8 days, gradually weakening.

Application of the substance Etamzilat

Prevention and control of bleeding: parenchymal and capillary bleeding, incl. traumatic, in surgery during operations on well-vascularized organs and tissues, during surgical interventions in dental (removal of cysts, granulomas, extraction of teeth, etc.), urological (prostatectomy, etc.), ophthalmic (keratoplasty, cataract removal, antiglaucoma operations, etc. surgical interventions), otolaryngological practice (tonsillectomy, microsurgical operations on the ear, etc.); intestinal, renal, pulmonary bleeding, metro- and menorrhagia with fibroma, secondary bleeding on the background of thrombocytopenia and thrombocytopathy, hypocoagulation, hematuria, intracranial hemorrhage (including in newborns and premature babies), nosebleeds with arterial hypertension, drug bleeding ( if they are not caused by anticoagulants), hemorrhagic vasculitis, hemorrhagic diathesis (including Werlhof disease, Willebrand-Jurgens disease, thrombocytopathy), vascular diseases with hemorrhagic syndrome, diabetic microangiopathy (hemorrhagic diabetic retinopathy, recurrent retinal hemorrhage, hemophthalmos).

Contraindications

Hypersensitivity, thrombosis, thromboembolism, acute porphyria, hemoblastosis in children.

Application restrictions

Hemorrhages on the background of anticoagulants.

Use during pregnancy and lactation

During pregnancy, it is possible if the expected effect of therapy outweighs the potential risk to the fetus (the safety of using etamsylate during pregnancy has not been established). At the time of treatment should stop breastfeeding.

Side effects of the substance Etamsylat

Dizziness, headache, flushing of the skin of the face, paresthesia of the lower extremities, decreased blood pressure, heartburn, heaviness in the epigastric region, allergic reactions.

Interaction

Pharmaceutically incompatible (in one syringe) with other drugs. Administration at a dose of 10 mg/kg 1 hour before dextrans (average molecular weight 30-40 thousand Da) prevents their antiaggregatory effect (administration after dextrans does not have a hemostatic effect). A combination with aminocaproic acid, menadione sodium bisulfite is acceptable.

Angioprotector and microcirculation corrector. Application: angiopathy, bleeding, hemorrhagic diathesis. Price from 120 rubles.

Analogues: Dicinon, Vikasol, Octanat.

What is the drug

Etamzilat - injections for intravenous, intramuscular injection. The drug is included in the group of hemostatics, angioprotectors.

Active ingredient and composition

1 ml of the solution contains 125 mg of the main ingredient - etamsylate.

Additional components in the composition of Etamzilat injections:

• sodium sulfite and disulfide;
• edetate disodium;
• water for injections.

Pharmacological properties

Etamzilat is a hemostatic agent, angioprotector.

Properties:

• restores the process of blood coagulation;
• increases elasticity, stability of capillary walls;
• normalizes blood microcirculation in various vessels.

Even with long-term therapy, blood clots do not form, since the drug does not affect the prothrombin index.

Pharmacodynamics and pharmacokinetics

The drug activates the synthesis of mucopolysaccharides and thromboplastin, which leads to the suppression of hemostatic activity.

After intravenous administration, the results of active action are noticeable after 10 minutes and are observed for 6-8 hours.

Approximately 72% of the active substance unchanged is excreted in the urine during the day. The half-life is 2 hours.

Indications for use

The drug is used to treat and prevent capillary bleeding. Etamzilat in ampoules is used in dentistry, ophthalmology, urology and gynecology, surgery.

Etamzilat - indications for use:

• diabetic angiopathy;
• uterine and other internal bleeding;
• surgical interventions - tonsillectomy, prostatectomy, keratoplasty, cataract removal, dental operations;
• injuries that are accompanied by bleeding;
• hemorrhagic diathesis.

The drug is sometimes prescribed for polymenorrhea to prevent the development of anemia.

Contraindications

Etamzilat is contraindicated in case of hypersensitivity to the components of drugs.

Method of application and dosage

The daily dose is 0.125-0.25 g, administered at intervals of 6-8 hours. The maximum allowable single dose is 0.375 g.

The solution can be soaked in a sterile dressing, used for wounds as a compress.

In childhood, during pregnancy and breastfeeding

The drug is not prescribed in the first trimester of pregnancy. At a later date, the drug is used with extreme caution under the constant supervision of a physician.

In pediatric practice, it is possible to use the drug, according to the relevant indications and the exact calculation of the required dose.

Side effects

Sometimes during therapeutic protocols, negative reactions appear:

• heartburn;
• heaviness in the epigastric region;
• headache, bouts of dizziness;
• redness of the skin of the face;
• decrease in systolic blood pressure;
• paresthesia of the lower extremities.

special instructions

The drug should not be used as the only drug for hemorrhage, which is caused by taking.

Overdose

There are no data on cases of the consequences of exceeding the dose in the instructions for use for Etamzilat.

drug interaction

Do not mix Etamzilat in the same syringe with any other medicines.

Analogues

Etamzilat's analogs:

• in composition - Dicinon;
• according to the therapeutic effect - Tincture of water pepper, Emaplag, Eltrombopah, Vikasol, Octanat.

Each drug has its own list of indications and contraindications. Replacement of the drug can be prescribed only by the attending physician.

One tablet of the drug contains sodium etamsylate 0.25 g and excipients.

Solution for injection contains etamzilate 0.125 per 1 ml + excipients (water for injection , sodium disulfite, disodium edetate, sodium sulfite anhydrous ).

Release form

Tablets convex round, packs of 50 and 100 pieces.

Injection in ampoules, colorless, transparent or slightly yellow. Packs of 1, 2 or 10 ampoules.

pharmachologic effect

Angioprotector, hemostatic .

Pharmacodynamics and pharmacokinetics

The drug activates the formation thromboplastin and mucopolysaccharides , thus showing hemostatic activity .

Normalizes the rate of blood clotting, increases the stability and elasticity of the walls, improves processes microcirculation even in the smallest vessels and capillaries.

It is noteworthy that the drug does not affect prothrombin index and does not contribute to education. If the drug is administered intravenously, the effect occurs within 10 minutes after the injection and lasts up to six to eight hours.

Indications for use

What are the pills for?

Etamzilat tablets are prescribed:

• with different origin;
• at ;
• during menstruation;
• during surgical interventions;
• in dentistry, ophthalmology, urology, surgery and gynecology ;
• with injuries and capillary bleeding ;
• polymenorrhea ;
• diabetic angiopathy ;
• hemorrhagic diathesis.

Often the drug is prescribed for heavy periods, to reduce blood loss and prevent the occurrence anemia .

Contraindications

• thromboembolism ;
• hemorrhage against the background of the reception anticoagulants .

Side effects

• heaviness in the stomach;
• reduced;

Application instruction of Etamzilat (Way and dosage)

The dosage, route of administration and duration of treatment should be determined by the physician.

According to the instructions for Etamzilat tablets, the drug is administered orally at 0.25-0.5 g (one or two tablets), divided into 3 or 4 doses. For children, the daily dose is 10-15 mg per kg of body weight, divided into 3 doses.

Sodium etamsylate in solution for injections are used in the form of injections ( intramuscularly, intravenously ) retrobulbarno or subconjunctival , depending on the indications.

The daily dose is 0.125-0.25 grams (for 3-4 applications), the maximum single dose is 0.75 g (parenterally - up to 0.375 g). External use is possible. A swab soaked in the preparation is applied to the wound.

The tool is also used in veterinary practice. The dosage for cats is 0.1 ml per kg of animal weight, injections are usually given twice a day.

Overdose

There are no data on cases of overdose.

Interaction

Do not mix in the same syringe with other drugs.

Terms of sale

A prescription in Latin or another language is required.

Storage conditions

In a dark place inaccessible to children, cool.

Best before date

Analogues

Coincidence in the ATX code of the 4th level:

Etamzilat during pregnancy and lactation

During pregnancy, the drug is prescribed with caution. The medicine is contraindicated in the first trimester of pregnancy.

Reviews about Etamzilat

Reviews the tablets are good. The drug quickly and permanently stops bleeding. Especially often they are used for heavy discharge during menstruation.

Etamzilat price (where to buy)

Price Etamzilat tablets about 104 rubles for 50 pieces.

Ampoules of sodium etamsylate for injections (2 ml) cost about 84 rubles for 10 pieces.

• Internet pharmacies in Russia Russia
• Internet pharmacies in Ukraine Ukraine

ZdravCity

Etamzilat solution i/v and i/m 125mg/ml 2ml n10North China Pharm.Corporation Ltd.